The prosperIV® Miami wellness program is excited to offer Semaglutide treatments! This advanced peptide boosts insulin secretion, lowers blood sugar levels, and helps curb appetite and cravings.
According to the Centers for Disease Control and Prevention (CDC), over 100.1 million people in the United States are affected by obesity. This condition is associated with most chronic diseases and is the leading cause of heart disease, stroke, diabetes, and even premature death. Additionally, obesity is linked to an increased risk of certain cancers. Even modest weight loss—around 5% to 10% of your total body weight—can yield significant health benefits, including improvements in mood, blood pressure, cholesterol levels, and blood sugar.
Semaglutide is a peptide that mimics the natural hormone glucagon-like peptide-1 (GLP-1), which is secreted by nutrient-responsive enteroendocrine cells (L cells) in the intestine. GLP-1 is a key incretin hormone involved in regulating glucose levels in the body.
By enhancing insulin secretion and lowering blood sugar levels, Semaglutide also helps reduce appetite and cravings. This peptide offers a valuable treatment option for adults with excessive body fat or a body mass index (BMI) over 30, making it an effective addition to a comprehensive weight management program.
Package includes: (monthly, non-refundable)
Indicated as a daily multivitamin maintenance supplement for adults and children aged 11 and older. The IV Vitamin Infusion contributes to intake of necessary vitamins toward maintaining the body’s normal resistance and repair processes.
Since Semaglutide affects how your body processes and digests food, it may initially cause gastrointestinal symptoms such as nausea, vomiting, stomach upset, diarrhea, tiredness, dizziness, and constipation. These symptoms typically lessen as your body adjusts to the medication. If any of these effects persist for more than three days or worsen, contact your provider, PCP, or pharmacist immediately.
To maximize the benefits of Semaglutide and support your weight management efforts, it’s crucial to adopt a healthy lifestyle. This includes:
Most individuals start to notice results within 8 to 12 weeks of starting Semaglutide treatment. Clinical trials indicate that participants can achieve an average weight reduction of 5-10% with weekly doses. It’s important to proceed gradually to avoid rapid weight loss and potential side effects.
*Patients should expect to commit for 3 months, each month is evaluated by the medical director before next steps are recommended.
Semaglutide has exhibited significant weight reducing property in various phase-3 SUSTAIN and PIONEER trials over dulaglutide and liraglutide. These results encouraged the researchers to carry out trials on weekly-once subcutaneous semaglutide for better management of obesity.
A cross over trial study on 30 obese subjects investigated the mechanism of semaglutide by studying energy intake, appetite sensation, gastric emptying, and postprandial glucose as well as triglyceride metabolism. Participants received weekly-once s.c. semaglutide (initially 0.25, then 0.5 and finally 1.0 mg with dose escalation) or placebo for 12-weeks, followed by a washout period of 5 to 7 weeks, and finally another 12-weeks treatment period. Semaglutide has shown about 24% drop in net calorie consumption with 5 kg weight reduction. Therefore, lower energy intake, enhanced satiation, less food craving, reduced body fat and weight loss are the plausible mechanism for the anorexic effect of semaglutide.
Semaglutide is a clinically approved drug for type 2 diabetes, obesity, and a clinical trial candidate for management of NASH, Parkinson’s and Alzheimer’s disease. Semaglutide is well tolerated and can be safely used in patients with renal, hepatic and CV diseases. Hepatoprotective and neuroprotective role of semaglutide in abating NASH and neurodegenerative diseases respectively has been proved in phase-2 trials and is still under study. It improves insulin resistance in the periphery as well as in the brain, reduces body weight, and reduces fat content in the liver by acting as an agonist on GLP-1 receptors. The efficacy of semaglutide in alleviating cardiac injury in COVID-19 patients with diabetes, obesity, hypertension and CV diseases is being studied. Based on drug repurposing strategy, researchers are trying their best to explore various therapeutic potentials of semaglutide. Clinical efficacy in different therapeutic fields proved semaglutide to be an indispensable treatment option for better management of “diabesity” and an emerging cynosure for management of NASH and neurodegenerative diseases.
You will love enhancing your vitamin drip infusions with a boost! These drip enhancers maximize results, add extra benefits to your IV, and can be personalized to your specific needs to help you feel even better.
